Abstract
Omeprazole, a gastric acid pump inhibitor, is repeatedly administered and is oxidatively metabolized mainly by polymorphic cytochrome P450 2C19. The prescribed dosage of omeprazole was discontinued or reduced in 47 of the 135 patients who received omeprazole alone in this survey, as recorded in the Japanese Adverse Drug Event Report database. The days to onset of omeprazole-related disorders were 3–4d (median) and 16d for intravenous 20–40mg and oral 20mg daily doses, respectively, in 34 patients for whom relevant data were available. The maximum plasma concentration of omeprazole was pharmacokinetically modeled after a single oral 40-mg dose in P450 2C19-defective poor metabolizers and was 2.4-fold higher than that in extensive metabolizers. The modeled area under the hepatic concentration curves of omeprazole in P450 2C19 poor metabolizers after virtual daily 40-mg doses for 7d was 5.2-fold higher than that in the extensive metabolizers. Omeprazole-induced P450 2C19 (approx. 2-fold), resulting in increased hepatic intrinsic clearance in repeated doses, was considered after the second day. Virtual plasma/hepatic exposure estimated using pharmacokinetic modeling in subjects with P450 2C19 poor metabolizers indicated that these exposure levels virtually estimated could be one of causal factors for unexpected hepatic disorders induced by prescribed omeprazole, such as those resulting from drug interactions with repeatedly co-administered medicines. The authors thank Hina Nakano, Haruka Nishimura, Atsuo Arai, Tsubasa Sasaki, and Manato Hosoi for their assistance. This work was supported in part by the Japan Agency for Medical Research and Development under Grant No. 24mk0101253h0103 and by the Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research 23K06217 and 23K14393. We are also grateful to David Smallbones for copyediting a draft of this article.
Author supplied keywords
Cite
CITATION STYLE
Adachi, K., Ohyama, K., Tanaka, Y., Murayama, N., Shimizu, M., Saito, Y., & Yamazaki, H. (2024). Modeled Hepatic/Plasma Exposures of Omeprazole Prescribed Alone in Cytochrome P450 2C19 Poor Metabolizers Are Likely Associated with Hepatic Toxicity Reported in a Japanese Adverse Event Database. Biological and Pharmaceutical Bulletin, 47(5), 1028–1032. https://doi.org/10.1248/bpb.b24-00145
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.